{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:40:02Z","timestamp":1748526002466,"version":"3.41.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.bcp.2015.07.021","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T17:19:01Z","timestamp":1437412741000},"page":"335-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["David J. Triggle: Medicinal chemistry, to pharmacology, calcium channels, and beyond"],"prefix":"10.1016","volume":"98","author":[{"given":"Michael J.A.","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.07.021_bib0005","unstructured":"Editor. Profile. An interview with David Triggle. ASSAY and Drug Development Technologies. 2004;2:1-8."},{"key":"10.1016\/j.bcp.2015.07.021_bib0010","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bcp.2012.08.005","article-title":"Nous sommes tous des bacteries: implications for medicine, pharmacology and public health","volume":"84","author":"Triggle","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bcp.2009.02.015","article-title":"The chemist as astronaut: searching for biologically useful space in the chemical universe","volume":"78","author":"Triggle","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drudis.2006.12.001","article-title":"Treating desires not diseases: a pill for every ill and an ill for every pill?","volume":"12","author":"Triggle","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2015.07.021_bib0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1021\/jm00330a003","article-title":"Potential folic acid antagonists. I. The antitumor and folic acid reductase inhibitory properties of 6-substituted 2,4-diamino-5arylazopyrimidines","volume":"8","author":"Hampshire","year":"1965","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0030","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1021\/jm00294a031","article-title":"Potential folic acid antagonists. 5. Synthesis and dihydrofolate reductase inhibitory activities of 2-amino-4,6-substituted-5arylazopyrimidines","volume":"4","author":"Chatterjee","year":"1971","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0035","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1021\/jm00294a036","article-title":"Potential folic acid antagonists. 6. Potential irreversible folate reductase inhibitors derived from 2,4-diamino-5-arylazopyrimidines","volume":"14","author":"Chatterjee","year":"1971","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0040","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0024-3205(65)90009-3","article-title":"The estrogenic activities of 16-alpha, 17alpha-and 16-beta, 17-beta-epoxy-1,3,5(10)-estratriene-3-ol","volume":"4","author":"May","year":"1965","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2015.07.021_bib0045","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1021\/jm00324a022","article-title":"6-Substituted 2,4-diamino-5-(4carbethoxyphenylazo) pyrimidines as potential precursors of tetrahydropteridine antimetabolites","volume":"9","author":"Chadwick","year":"1966","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1021\/jm00309a037","article-title":"Potential folic acid antagonists. 3. The antitumor and folate reductase inhibitory properties of some irreversibly acting 6-N-substituted 2,4,6triamino-5-(4-carbethoxyphenylazo) pyrimidines","volume":"11","author":"Hampshire","year":"1968","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/jps.2600570332","article-title":"Cholinergic receptor I. Cholinomimetic activities of some analogs of cis-2methyl-4-dimethylaminomethyl-1,dioxolane methiodide","volume":"57","author":"May","year":"1968","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2015.07.021_bib0060","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1021\/jm00302a029","article-title":"Studies on the cholinergic receptor 3. Parasympatholytic properties of cis-and trans-4-dimethylaminomethyl-2-phenyl-1, 3-dioxolane methiodide","volume":"12","author":"May","year":"1969","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0022-5193(73)90168-9","article-title":"Quantitative aspects of drug-receptor interactions. I. Ca2+ and cholinergic receptor activation in smooth muscle: a basic model for drug-receptor interactions","volume":"40","author":"Chang","year":"1973","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0070","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1021\/jm00305a059","article-title":"Studies on the cholinergic receptor. IV. The synthesis and muscarinic activity of 3,7-dimethyl-2,4-dioxo-7-azaspiro[3.4]octane methiodide","volume":"12","author":"Ridley","year":"1969","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0026-895X(25)14714-7","article-title":"Studies on the noradrenaline alpha-receptor. I. Techniques of receptor isolation. The distribution and specificity of action of N-(2-bromoethyl)-nethyl-1-naphthylmethylamine, a competitive antagonist of noradrenaline","volume":"3","author":"Moran","year":"1967","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0080","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0022-5193(65)90047-0","article-title":"The mechanism of interaction of 2-halogenoethylamines at the noradrenaline receptor","volume":"9","author":"Kimelberg","year":"1965","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0022-5193(65)90116-5","article-title":"The reactions of 2-halogenoethylamines at the noradrenaline receptor-storage complex","volume":"9","author":"Kimelberg","year":"1965","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0090","first-page":"173","article-title":"2-Halogenoethylamines and receptor analysis","volume":"2","author":"Triggle","year":"1965","journal-title":"Adv. Drug Res."},{"key":"10.1016\/j.bcp.2015.07.021_bib0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev.pa.12.040172.001153","article-title":"Adrenergic receptors","volume":"12","author":"Triggle","year":"1972","journal-title":"Annu. Rev. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.2042-7158.1973.tb10638.x","article-title":"On the question of subclassification of a-adrenoceptors","volume":"25","author":"Janis","year":"1973","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0105","first-page":"687","article-title":"A brief history of calcium channel discovery","volume":"vol. 13","author":"Tsien","year":"2011"},{"key":"10.1016\/j.bcp.2015.07.021_bib0110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/pr.57.4.5","article-title":"International union of pharmacology XLV!!! nomenclature and XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels","volume":"57","author":"Catterall","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2015.07.021_bib0115","first-page":"13","article-title":"1983 History of calcium antagonists","volume":"52","author":"Fleckenstein","year":"1983","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2015.07.021_bib0120","doi-asserted-by":"crossref","first-page":"1B","DOI":"10.1016\/0002-9149(87)90077-4","article-title":"Classification of calcium antagonists","volume":"59","author":"Godfraind","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0125","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1139\/y73-094","article-title":"Effect of diazoxide on aortic reactivity to calcium in spontaneously hypertensive rats","volume":"51","author":"Janis","year":"1973","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0022-5193(73)90169-0","article-title":"Quantitative aspects of drug-receptor interactions. II. The role of Ca2+ men in desensitization and spasmolytic activity","volume":"40","author":"Chang","year":"1973","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.78.1.174","article-title":"Pharmacology of agents that affect calcium. Agonists and antagonists","volume":"78","author":"Triggle","year":"1980","journal-title":"Chest"},{"key":"10.1016\/j.bcp.2015.07.021_bib0140","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1139\/y79-052","article-title":"The effect of Ca2+ antagonists on mechanical responses and Ca2+ movements in guinea pig ileal longitudinal smooth muscle","volume":"57","author":"Rosenberger","year":"1979","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2007.01.016","article-title":"Calcium channel antagonists: clinical uses \u2013 past, present and future","volume":"74","author":"Triggle","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0150","first-page":"I17","article-title":"Calcium antagonists. Some chemical-pharmacologic aspects","volume":"52","author":"Triggle","year":"1983","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2015.07.021_bib0155","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1021\/jm00360a001","article-title":"New developments in Ca2+ channel antagonists","volume":"26","author":"Janis","year":"1983","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0160","first-page":"213","article-title":"Recent development in calcium channel antagonists","volume":"8","author":"Triggle","year":"1989","journal-title":"Magnesium"},{"key":"10.1016\/j.bcp.2015.07.021_bib0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1749-6632.1989.tb24099.x","article-title":"Calcium channels in smooth muscle. Properties and regulation","volume":"560","author":"Triggle","year":"1989","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.021_bib0170","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0165-6147(89)90051-5","article-title":"1,4-Dihydropyridine activators and antagonists: structural and functional distinctions","volume":"10","author":"Triggle","year":"1989","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2015.07.021_bib0175","first-page":"112","article-title":"New ligands for L-type Ca2+ channels","volume":"990","author":"Rampe","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2015.07.021_bib0180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.1991.tb36487.x","article-title":"Synthetic organic ligands active at voltage-gated calcium channels","volume":"635","author":"Triggle","year":"1991","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"suppl. IV","key":"10.1016\/j.bcp.2015.07.021_bib0185","first-page":"49","article-title":"Calcium antagonists. History and perspective, review","volume":"12","author":"Triggle","year":"1990","journal-title":"Stroke"},{"key":"10.1016\/j.bcp.2015.07.021_bib0190","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1139\/y90-224","article-title":"Calcium, calcium channels, and calcium channel antagonists","volume":"68","author":"Triggle","year":"1990","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"suppl. 10","key":"10.1016\/j.bcp.2015.07.021_bib0195","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199118101-00002","article-title":"Calcium-channel drugs: structure-function relationships and selectivity of action","volume":"18","author":"Triggle","year":"1991","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0200","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/chir.530030504","article-title":"Chiral aspects of drug action at ion channels: a commentary on the stereoselectivity of drug actions at voltage-gated ion channels with particular reference to verapamil actions at the Ca2+ channel","volume":"3","author":"Kwon","year":"1991","journal-title":"Chirality"},{"key":"10.1016\/j.bcp.2015.07.021_bib0205","doi-asserted-by":"crossref","first-page":"422S","DOI":"10.1093\/ajh\/4.7.422S","article-title":"Sites, mechanisms of action, and differentiation of calcium channel antagonists","volume":"4","author":"Triggle","year":"1991","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.bcp.2015.07.021_bib0210","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3949\/ccjm.59.6.617","article-title":"Calcium-channel antagonists: mechanisms of action, vascular selectivities, and clinical relevance","volume":"59","author":"Triggle","year":"1992","journal-title":"Cleveland Clin. J. Med."},{"key":"10.1016\/j.bcp.2015.07.021_bib0215","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1749-6632.1994.tb44415.x","article-title":"Molecular pharmacology of voltage-gated calcium channels","volume":"747","author":"Triggle","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.021_bib0220","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0022-3565(25)10629-0","article-title":"Calcium channel antagonists: cardiovascular selectivity of action","volume":"274","author":"Sun","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.021_bib0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0002-9149(96)00732-1","article-title":"Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist","volume":"78","author":"Triggle","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0230","doi-asserted-by":"crossref","first-page":"80S","DOI":"10.1016\/S0895-7061(98)00004-1","article-title":"The physiological and pharmacological significance of cardiovascular T-type, voltage-gated calcium channels","volume":"11","author":"Triggle","year":"1998","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.bcp.2015.07.021_bib0235","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/154065803770381075","article-title":"Drug targets in the voltage-gated calcium channel family: why some are and some are not","volume":"1","author":"Triggle","year":"2003","journal-title":"ASSAY Drug Dev. Technol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0240","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1023\/A:1023632419813","article-title":"1,4-Dihydropyridines as calcium channel ligands and privileged structures","volume":"23","author":"Triggle","year":"2003","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0245","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/138161206775474503","article-title":"l-type calcium channels","volume":"12","author":"Triggle","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2015.07.021_bib0250","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/0006-291X(82)91436-X","article-title":"High affinity binding of a calcium channel antagonist to smooth and cardiac muscle","volume":"104","author":"Bolger","year":"1982","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2015.07.021_bib0255","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1101\/SQB.1983.048.01.030","article-title":"Chemical and pharmacological approaches to the definition and quantitation of calcium channels","volume":"48","author":"Gengo","year":"1983","journal-title":"Cold Spring Harbor Symp. Quant. Biol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0260","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0022-3565(25)33587-1","article-title":"Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle","volume":"225","author":"Bolger","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"258","key":"10.1016\/j.bcp.2015.07.021_bib0265","first-page":"9344","article-title":"Molecular properties of the slow inward calcium channel. Molecular weight determinations by radiation inactivation and covalent affinity labeling","volume":"983","author":"Venter","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0270","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1016\/0006-2952(84)90066-2","article-title":"Comparison of high affinity binding of calcium channel blocking drugs to vascular smooth muscle and cardiac sarcolemmal membranes","volume":"33","author":"Sarmiento","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0275","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1139\/y87-228","article-title":"Comparative aspects and temperature dependence of [3H]1,4-dihydropyridine Ca2+ channel antagonist and activator binding to neuronal and muscle membranes","volume":"65","author":"Rampe","year":"1987","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"suppl. 4","key":"10.1016\/j.bcp.2015.07.021_bib0280","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1097\/00005344-198806124-00018","article-title":"Potential-dependent interactions of nitrendipine and related 1,4-dihydropyridines in functional smooth muscle preparations","volume":"12","author":"Triggle","year":"1988","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0285","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/jm00397a005","article-title":"Crystal structures and pharmacologic activities of 1,4-dihydropyridine calcium channel antagonists of the isobutyl methyl 2,6-dimethyl-4-(substituted phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (nisoldipine) series","volume":"31","author":"Fossheim","year":"1988","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0290","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(25)00314-3","article-title":"[3H]BAY K 8644, a 1,4-dihydropyridine Ca++ channel activator: characteristics of binding to high and low affinity sites in cardiac membranes","volume":"241","author":"Sarmiento","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2015.07.021_bib0295","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0006-291X(89)92524-2","article-title":"Homologous regulation of voltage-dependent calcium channels by 1,4-dihydropyridines","volume":"160","author":"Skatteb\u00f8l","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2015.07.021_bib0300","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/med.2610090203","article-title":"Ca2+ channel ligands: structure-function relationships of the 1,4-dihydropyridines","volume":"9","author":"Triggle","year":"1989","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2015.07.021_bib0305","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1021\/jm00170a032","article-title":"4-Isoxazolyl-1,4-dihydropyridines: biological, theoretical, and structural studies","volume":"33","author":"Natale","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.07.021_bib0310","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00129749","article-title":"Molecular level model for the agonist\/antagonist selectivity of the 1,4-dihydropyridine calcium channel receptor","volume":"5","author":"Langs","year":"1991","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bcp.2015.07.021_bib0315","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0026-895X(25)08953-9","article-title":"Pharmacologic and radioligand binding studies of 1,4-dihydropyridines in rat cardiac and vascular preparations: stereoselectivity and voltage dependence of antagonist and activator interactions","volume":"41","author":"Zheng","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0320","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bcp.2015.06.017","article-title":"Collaborating with Alexander Scriabine and the Miles Institute for Preclinical Pharmacology","volume":"98","author":"Janis","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0325","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.bcp.2015.07.003","article-title":"The Triggle effect","volume":"98","author":"Snutch","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0330","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bcp.2015.06.019","article-title":"From B.Sc. to Ph.D, My shuffle off to Buffalo","volume":"98","author":"Bolger","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0335","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bcp.2015.06.026","article-title":"Professionalism an exemplar for the sciences","volume":"98","author":"Wurm-Schaar","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2015.07.021_bib0340","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bcp.2015.07.005","article-title":"Lessons learned from a novel calcium-channel protagonist and person","volume":"98","author":"Dillon","year":"2015","journal-title":"Biochem. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215003913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215003913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:07:32Z","timestamp":1748524052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215003913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0006295215003913"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.07.021","relation":{},"ISSN":["0006-2952"],"issn-type":[{"type":"print","value":"0006-2952"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"David J. Triggle: Medicinal chemistry, to pharmacology, calcium channels, and beyond","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}